Syneos Health Commercial Solutions
Going Global: A “Three-V” Framework For Biopharma Market Expansion
Kipp Kreutzberg
Global expansion remains one of the most powerful ways for biopharma companies to unlock asset value and reach the broadest possible patient populations. Yet, success across major regions, such as the United States, Europe, and the Asia Pacific, depends on navigating an intricate mix of regulatory, operational, and cultural factors. Scaling beyond a home market requires foresight, coordination and an understanding of how market dynamics differ by region.
Getting Real About Globalization
Sponsors are always under intense pressure to get their first launch in the market of entry right, while simultaneously preparing for rapid global expansion into the broadest, highest-value addressable markets to drive a positive return on investment. But achieving speed on the road to expansion must account for multiple challenges that can make or break success. These include:
• Resource constraints. Operational limitations can slow market activation, even when the pressure to move quickly is high.
• Risk exposure. Insufficient investment flexibility and optionality can constrain future choices, limiting agility and elevating risk exposure.
• Complexity. Uncharted territory makes it difficult to know where to start, what to prioritize and what comes next.
• Nonalignment. The scope of decision-making required for market expansion necessitates ongoing alignment among siloed and divergent stakeholders.
At its core, commercialization success is a function of price multiplied by volume. Global expansion seeks to maximize both—but doing so requires nuanced, marketspecific strategies. Companies must assess whether unmet needs, value perceptions and access pathways align across borders. Success requires regional alignment combined with deep local execution.
Managing Risk and Uncertainty
Entering new markets is fraught with common pitfalls that include:
• Underestimating the cost and time of pre-launch preparation.
• Overgeneralizing unmet need, customer experience or demand signals across regions.
• Misjudging how labor laws and hiring practices influence team structure and scalability.
• Under-appreciating the impact of unique cultural differences on stakeholder engagement and marketing strategy.
• Treating regulatory approval as the finish line rather than a midpoint.
Avoiding these pitfalls in the lead-up to globalization requires:
• A clear understanding of how local decisions impact global asset value.
• Integrated cross-functional planning early in development—ideally by phase II or III of clinical trials— not post-approval.
• Flexible operational models that adapt to market feedback and local business operating requirements without compromising asset control.
• The ability to tap regional centers of excellence and insights hubs that help inform global strategy with local intelligence.
A Closer Look
The distinct market dynamics shaping commercialization strategies across the US, Europe, Japan and China each demand tailored approaches informed by local systems, stakeholder behaviors and regulatory frameworks. Global biopharma expansion requires region-specific strategies.
For example, in the US, success hinges on navigating payer complexity, engaging informed patients, and aligning with advocacy groups. Europe demands tailored launch sequencing, entity planning and GDPR-compliant engagement across fragmented markets. Japan emphasizes precision in pricing, local hiring under strict labor laws, and relationship-driven marketing that aligns with cultural expectations. In China, sponsors must blend centralized policy navigation with hyper-local execution, taking into account traditional medicine, family-driven decisions, and regulatory constraints.
“Commercialization success lies in mastering both sides of the equation, price and volume, through locally informed, globally aligned strategies.”
Across all markets, deep local insight, cultural fluency and strategic agility are essential to building trust, accelerating access and sustaining long-term impact.
Charting a Course for Global Expansion: The Three “Vs”
When it comes to accelerating global expansion and preserving go-to-market optionality, it helps to think of the journey ahead as a simplified construct of Vision— Venture—Voyage.
• Vision. This is about uncovering unmet needs and identifying opportunities to advance the standard of care, as well as understanding the competitive advantage.
• Venture. This is foremost about an asset/brand’s core value proposition and creating a forecasting model that encompasses the most important value drivers. It is about generating insights and proof sources that underpin why the proposed venture is viable. Investors have to believe in the asset and the team that is curating the asset opportunity.
• Voyage. This building block is about the detailed planning and executional excellence that mitigates risk and optimizes outcome, for example:
• Assume self-commercialization as a probable scenario
• Assume partnership or sale of asset as possible scenarios
• Develop a credible commercialization plan
• Identify and mitigate risks o Raise enough funding to fail successfully
Conclusion
Successful globalization requires a clear understanding of how healthcare is accessed, financed, and delivered in each market—paired with the strategic discipline to construct tailored pathways that reflect those realities. Companies must align their commercialization efforts to intensely localized patient journeys, health system structures and regulatory frameworks. Doing so often means challenging assumptions, adapting go-to-market models and investing selectively in local expertise and partnerships. Ultimately, successful globalization requires organizations to strike a deliberate balance between a consistent global strategy and responsiveness to regional dynamics.
